Keping Chen

Prof. Dr. Keping Chen

1. School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Life Sciences
Verified
Journal Article
Closed access
HZHuan Zuo
Huan Zuo
LCLiang Chen
Liang Chen
MKMing Kong
Ming Kong
LQLipeng Qiu
Lipeng Qiu
PLPeng Lü
Peng Lü
Keping ChenKeping Chen
Keping Chen

13 December 2019 in Toxins
Verified
Journal Article
Open access
PDF file
HWHong Wu
Hong Wu
Liang ChenLiang Chen
Liang Chen
FZFeifei Zhu
Feifei Zhu
XHXu Han
Xu Han
LSLindan Sun
Lindan Sun
Keping ChenKeping Chen
Keping Chen
Resveratrol, a natural polyterpenoid, can scavenge reactive oxygen species in vivo to carry out the functions of antioxidation and antiaging. Resveratrol’s anti-cancer capability has attracted widespread attention, but its molecular mechanism has not been systematically explained. In this study, by comparing the activity of normal cell lines and cancer cell lines after treating with resveratrol, it was found that resveratrol has more significant cytotoxicity in cancer cell lines. Resveratrol could play a toxic role through inducing apoptosis of the cancer cell in a time- and concentration-dependent manner. A total of 330 significantly differential genes were identified through large-scale transcriptome sequencing, among which 103 genes were upregulated and 227 genes were downregulated. Transcriptome and qRT-PCR data proved that a large number of genes related to cell cycle were differentially expressed after the treatment of resveratrol. The changes of cell cycle phases at different time points after treating with resveratrol were further detected, and it was found that the cells were arrested in the S phase because of the percentage of cells in S phase increased and cells in G1/G0 phase decreased. In conclusion, resveratrol can inhibit the proliferation of 4T1 cancer cells by inhibiting cell cycle and inducing apoptosis.

1 August 2018 in European Journal of Pharmacology
Verified
Journal Article
Closed access
QGQi Ge
Qi Ge
LCLiang Chen
Liang Chen
MTMin Tang
Min Tang
SZShu Zhang
Shu Zhang
LLLanlan Liu
Lanlan Liu
Keping ChenKeping Chen
Keping Chen

29 October 2018 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
NANouara Abdelli
Nouara Abdelli
LPLü Peng
Lü Peng
Keping ChenKeping Chen
Keping Chen

1 December 2017 in Life Sciences
Verified
Journal Article
Closed access
LQLipeng Qiu
Lipeng Qiu
QTQi Tang
Qi Tang
GLGuohui Li
Guohui Li
Keping ChenKeping Chen
Keping Chen

1 June 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
VAVivian Andoh
Vivian Andoh
DODickson Kofi Wiredu Ocansey
Dickson Kofi Wiredu Ocansey
HNHassan Naveed
Hassan Naveed
NWNaijian Wang
Naijian Wang
Liang ChenLiang Chen
Liang Chen
FMFei Mao
Fei Mao
The relentless pursuit of effective cancer diagnosis and treatment strategies has led to the rapidly expanding field of nanotechnology, with a specific focus on nanocomposites. Nanocomposites, a combination of nanomaterials with diverse properties, have emerged as versatile tools in oncology, offering multifunctional platforms for targeted delivery, imaging, and therapeutic interventions. Nanocomposites exhibit great potential for early detection and accurate imaging in cancer diagnosis. Integrating various imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), and fluorescence imaging, into nanocomposites enables the development of contrast agents with enhanced sensitivity and specificity. Moreover, functionalizing nanocomposites with targeting ligands ensures selective accumulation in tumor tissues, facilitating precise imaging and diagnostic accuracy. On the therapeutic front, nanocomposites have revolutionized cancer treatment by overcoming traditional challenges associated with drug delivery. The controlled release of therapeutic agents from nanocomposite carriers enhances drug bioavailability, reduces systemic toxicity, and improves overall treatment efficacy. Additionally, the integration of stimuli-responsive components within nanocomposites enables site-specific drug release triggered by the unique microenvironment of the tumor. Despite the remarkable progress in the field, challenges such as biocompatibility, scalability, and long-term safety profiles remain. This article provides a comprehensive overview of recent developments, challenges, and prospects, emphasizing the transformative potential of nanocomposites in revolutionizing the landscape of cancer diagnostics and therapeutics. In Conclusion, integrating nanocomposites in cancer diagnosis and treatment heralds a new era for precision medicine.